H.B. Fuller (FUL) Stock Could Be 8% Undervalued After Its 2025 Sustainability Report
H.B. Fuller Company FUL | 0.00 |
H.B. Fuller (FUL) is in focus after publishing its 2025 Sustainability Report, which sets out 2030 goals on greenhouse gas emissions, water use, and waste intensity, and links these efforts to operations and customer demand.
Recent trading suggests momentum in H.B. Fuller stock has been picking up, with a 30 day share price return of 11.27% and a 90 day share price return of 28.74%. The 1 year total shareholder return of 21.62% gives investors context on how this shorter term move fits into the longer record.
If this kind of sustainability focused story is on your radar, it may also be a good moment to see what else is moving through the 20 top founder-led companies
With H.B. Fuller stock up 11.27% over 30 days and 28.74% over 90 days, and trading about 10% below analyst price targets, the question is whether there is still a buying opportunity or if markets are already pricing in future growth.
Most Popular Narrative: 8% Undervalued
Compared with H.B. Fuller’s last close at $64.77, the most followed narrative pins fair value around $70, implying a modest discount in the current price.
H.B. Fuller is focused on maintaining pricing discipline and securing additional pricing gains, particularly in the HHC segment, which is expected to improve EBITDA margins as raw material cost pressures subside. This pricing strategy is likely to positively impact revenue and margins.
Want to see what sits behind that margin story for H.B. Fuller? The narrative is based on steady revenue expansion, firmer profitability and a future earnings multiple that must hold up across the next few years.
Result: Fair Value of $70.43 (UNDERVALUED)
However, H.B. Fuller investors still face real swing factors, including pressure on solar related revenue and questions around leverage if further acquisitions proceed.
Another View: H.B. Fuller Stock Through a Different Lens
The earlier narrative framed H.B. Fuller as modestly undervalued around a fair value of about $70 per share. However, on a simple P/E basis the picture is less forgiving. The current P/E of 22.1x sits above an estimated fair ratio of 18.9x, which signals a risk that the market could compress the multiple toward that lower level.
At the same time, H.B. Fuller trades below both the US Chemicals industry average P/E of 27.5x and a peer average of 25.6x, so anyone focusing on relative pricing might reach a very different conclusion about upside and downside. Which lens you trust more will probably depend on how confident you are in the earnings path that underpins those numbers.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out H.B. Fuller for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 48 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
Mixed signals on H.B. Fuller so far? With both risks and rewards on the table, this is a good moment to review the data, weigh the trade offs, and see the 4 key rewards and 1 important warning sign
Looking for more investment ideas beyond H.B. Fuller?
If you are weighing what to do with H.B. Fuller stock, do not stop here. Spread your research across other clear, data backed ideas that fit your style.
- Target potential high growth stories early by scanning 24 elite penny stocks with strong financials before they sit firmly on everyone else's radar.
- Zero in on quality at a discount by running through the 48 high quality undervalued stocks while valuations still look appealing.
- Build a steadier income stream by reviewing companies in the 8 dividend fortresses and see which yields line up with your goals.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
